Group One Trading
CADL icon

Group One Trading’s Candel Therapeutics CADL Stock Holding History

Group One Trading’s Portfolio CADL Stock Details CADL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$109K Buy
10,600
+4,000
+61% +$30.2K ﹤0.01% 4781
2026
Q1 		$32.3K Buy
6,600
+3,200
+94% +$17.4K ﹤0.01% 5603
2025
Q4 		$19.2K Sell
3,400
-7,900
-70% -$42.5K ﹤0.01% 6363
2025
Q3 		$57.6K Sell
11,300
-8,200
-42% -$47.4K ﹤0.01% 5835
2025
Q2 		$98.7K Sell
19,500
-23,000
-54% -$118K ﹤0.01% 4978
2025
Q1 		$240K Buy
42,500
+35,500
+507% +$290K ﹤0.01% 3832
2024
Q4 		$60.8K Buy
+7,000
New +$41.4K ﹤0.01% 4910
2024
Q3 		– Sell
-600
Closed -$3.72K – 6689
2024
Q2 		$3.72K Buy
+600
New +$4.5K ﹤0.01% 6068

Other funds holding CADL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $2.67B AUM 169.09% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Group One Trading's CADL Position: Q2 2026 in Review

Group One Trading sold out of Candel Therapeutics (CADL) in Q2 2026, closing a stake of 8,760 shares — an estimated $66.2K sold.

Group One Trading first reported a position in CADL in Q4 2025 and held it in 2 quarters. The position peaked at $50.3K in Q4 2025. 138 funds tracked by Wall St. Rank hold CADL as of Q2 2026.

  • Group One Trading reported no remaining Candel Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Group One Trading sold 8,760 Candel Therapeutics shares in Q2 2026, an estimated $66.2K.
  • Group One Trading first reported a position in Candel Therapeutics in Q4 2025 and held it in 2 quarters.
  • Group One Trading's Candel Therapeutics position peaked at $50.3K in Q4 2025.
  • 138 funds tracked by Wall St. Rank held Candel Therapeutics as of Q2 2026.

Based on Group One Trading's 13F filing for Q2 2026, filed 14 Aug 2026.